Drug-drug interaction Satellite Workshop

Slides:



Advertisements
Similar presentations
TB & HIV Infection: Treatment
Advertisements

ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.
Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.
ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.
Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.
Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.
A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
Scott Butler Infection Innovative Medicines Group AstraZeneca R&D, Boston CPTR Workshop, 2012 Arlington, VA AZD5847 Oxazolidinone for the treatment of.
HIV and Malaria Dr Jane Achan Dept of Pediatrics, Makerere University College of Health Sciences Prof. Moses Kamya Makerere University College of Health.
The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.
Developing child-appropriate formulations: what is in the research pipeline for paediatric ARVS? July 17, 2011 Challenges in the Development & Procurement.
Summary of ARV prescribing guidelines in London These slides summarise the recommendations by the London HIV Consortium for prescribing antiretrovirals.
Management of HIV infection in HIV/HCV co-infected patients Mark Hull, MD, MHSc, FRCPC Division of AIDS University of British Columbia.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Switch to ATV + r-containing regimen - SWAN - SLOAT.
Malaria treatment. Dr abdulrahman al shaikh.. Introduction million patients died because of malaria every year. Most deaths due to Plasmodium Falciparum.
Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.
World Health Organization
Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.
Moving forward in the diagnosis of infectious diseases in developing countries: a focus on malaria Forum organized by Fondation Mérieux & the Roll Back.
Case Discussion: Complications after ART Weerawat Manosuthi, MD Department of Medicine Bamrasnaradura Infectious Diseases Institute, Ministry of Public.
Generic Name: combination of artemether and lumefantrine Brand Name: Coartem Dosage form : tablet Manufuctuing: Novartis is used to treat a parasitic.
ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.
Effects of nucleoside analogues versus ritonavir boosted protease inhibitors on lipid levels – analysis of 12 clinical trials in 4231 antiretroviral naïve.
De Luca A 1,2, Bracciale L 1, Doino M 1, Fabbiani M 1, Sidella L 1, Marzocchetti A 1, Farina S 1, D’Avino A 1, Cauda R 1, Di Giambenedetto S 1 Safety and.
Welcome to I-TECH HIV/AIDS Clinical Seminar Series October 21, 2010 Malaria/HIV Interactions: Clinical Update Paula Brentlinger, MD, MPH.
Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.
TUBERCULOSIS IN THE AGE OF HIV Dr. Terry Baker Physician National Chest Hospital.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
1 Advantages and risks for a child to be exposed to the triple prophylaxis during pregnancy and breastfeeding What is the best for the child ? Pr C. Courpotin.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Malaria Case management KPA conference. Presentation outline  Introduction  National malaria strategy  Case management targets  AMFm subsidy  The.
Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Issues in malaria diagnosis and treatment May 31, 2007 Jacek Skarbinski, MD Malaria Branch Centers for Disease Control and Prevention.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Artemisinin-based Products Dr. Henrike Potthast
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,
02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.
WORLD AIDS DAY Zero new HIV infections Zero discrimination Zero AIDS-related deaths.
Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) M Shelton, S Ford, M Anderson, S Murray, J Ng-Cashin XVI.
International Congress of Chemotherapy
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Antiretrovirals III: Pharmacokinetics and Drug Interactions
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Is antimalarial treatment in pregnant women as effective as that in non- pregnant women? Elizabeth Juma, Rashid Aman, Florence Oloo, Bernhards Ogutu Centre.
TB-H V Co-infection by Dr. Ker Hong Bee 11. LEARNING OBJECTIVES To know & understand about TB-HIV co- infection in relation to:- – interaction & prevalence.
Hot Topics in Infectious Diseases Giuseppe Nunnari.
Post-discharge chemoprevention of malaria in transfused children; a randomized trial in Uganda & Kenya R Idro, R Opoka, A Dhabangi, F TerKuile, and K Phiri.
Neurologic Effects Associated With Efavirenz Generally Mild, Transient Slideset on: Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological.
Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.
Antimalarial Drugs.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Atazanavir + ritonavir vs. Lopinavir-ritonavir CASTLE Study
What’s New in the Perinatal Guidelines
LPV-RTV versus LPV-RTV + ZDV-3TC in Treatment-Naïve MONARK Trial
Why Dolutegravir? Daniel R. Kuritzkes, M.D.
Comparison of NNRTI vs PI/r
Presentation transcript:

Drug-drug interaction Satellite Workshop HIV Malaria Co-infection M Lamorde MRCP, PhD

Malaria and HIV Malaria: major cause of morbidity and mortality in tropics Treatment: artemisinin derivatives are critical for eradication of plasmodium falciparum (responsible for greatest burden) Epidemiology: significant geographic overlap with HIV Complex interactions: pathogenesis, therapeutics Focus: malaria HIV drug interactions in resource-limited settings

Uganda: recommended drugs Malaria treatment Uncomplicated malaria artemether/lumefantrine artesunate/amodiaquine Alternative: DHA/piperaquine (previously oral quinine) Severe malaria parenteral quinine parenteral artesunate

Uganda: recommended drugs Antiretroviral therapy First-line (NNRTI-based) efavirenz nevirapine Second-line (PI-based) lopinavir/ritonavir atazanavir/ritonavir

Uganda: recommended drugs Antiretroviral therapy First-line (NNRTI-based) efavirenz nevirapine Second-line (PI-based) lopinavir/ritonavir atazanavir/ritonavir CYP3A4 inducers

Uganda: recommended drugs Antiretroviral therapy First-line (NNRTI-based) efavirenz nevirapine Second-line (PI-based) lopinavir/ritonavir atazanavir/ritonavir CYP3A4 inhibitors

Potential for interactions with ARVs Antimalarial drug Metabolic pathway Quinine CYP3A4, 2C19 Artesunate/amodiaquine CYP3A4, 2A6 Artemether/lumefantrine CYP2C19, 3A4 Chloroquine CYP2C8, 2D6, 3A4 Atovaquone/proguanil Glucuronidation, 2C19 ATOVAQUONE/PROGUANIL NOT MENTIONED IN UGANDA GUIDELINES SO WILL YOU COMMENT?

Potential for interactions with ARVs Antimalarial drug Metabolic pathway Quinine CYP3A4, 2C19 Artesunate/amodiaquine CYP3A4, 2A6 Artemether/lumefantrine CYP2C19, 3A4 Chloroquine CYP2C8, 2D6, 3A4 Atovaquone/proguanil Glucuronidation, 2C19 ATOVAQUONE/PROGUANIL NOT MENTIONED IN UGANDA GUIDELINES SO WILL YOU COMMENT?

Potential interactions Malaria treatment Uncomplicated malaria artemether/lumefantrine artesunate/amodiaquine Alternative: DHA/piperaquine (previously oral quinine) Severe malaria parenteral quinine parenteral artesunate Antiretroviral therapy First-line (NNRTI-based) efavirenz nevirapine Second-line (PI-based) lopinavir/ritonavir atazanavir/ritonavir

Case May 2012 Loss of appetite, fever, occasional vomiting X 1 week NGN, F, 43 yrs, HIV diagnosis (2005) Management CTX 960 mg OD (since 2005) AZT/3TC/EFV (since 2008) baseline CD4 108 cells/µL CD4 (2011) 765 cells/µL May 2012 Loss of appetite, fever, occasional vomiting X 1 week Self medication with antimalarials (likely artemether/lumefantrine) No improvement NICE CASE. MAYBE STOP AFTER THE NO IMPROVEMENT TO GET PANEL COMMENTS BEFORE PROCEEDING TO THE DIAGNOSIS? Infectious Diseases Institute, Kampala

plasmodium falciparum Case NGN, F, 43 yrs, HIV diagnosis (2005) Management CTX 960 mg OD (since 2005) AZT/3TC/EFV (since 2008) baseline CD4 108 cells/µL CD4 (2011) 765 cells/µL May 2012 Loss of appetite, fever, occasional vomiting X 1 week Self medication with antimalarials (likely artemether/lumefantrine) No improvement NICE CASE. MAYBE STOP AFTER THE NO IMPROVEMENT TO GET PANEL COMMENTS BEFORE PROCEEDING TO THE DIAGNOSIS? plasmodium falciparum

Options: AZT/3TC/EFV plus quinine ? Will you be asking the Panel if they would treat this patient with Quinine?

Options: AZT/3TC/EFV plus quinine EVIDENCE: No data for efavirenz, some data for nevirapine PK: In healthy volunteers receiving nevirapine, 33% lower quinine AUC and 36% lower Cmax Soyinka et al. J Pharm Pharmacol (2009) Efficacy: 1 case report of worsening malaria during quinine therapy Uriel A. Int J STD AIDS (2011) Will you be asking the Panel if they would treat this patient with Quinine?

Options: AZT/3TC/EFV plus artesunate/ amodiaquine ? Question to Panel – is this a realistic option?

Options: AZT/3TC/EFV plus artesunate/ amodiaquine EVIDENCE: Safety: First two healthy volunteers in a trial developed significant transaminase elevations with amodiaquine exposure increased 115% & 302%. No artemisinin data. German P et al. J CID (2007) Safety: Higher risk of neutropenia among HIV-infected children on antiretroviral therapy Gasasira AF et al. CID (2008) Question to Panel – is this a realistic option?

Options: AZT/3TC/EFV plus artemether/ lumefantrine This is what we did ? So the issues now are: the patient has already self-medicated with ART/LUM; the magnitude of the interaction To Panel – would you proceed?

Options: AZT/3TC/EFV plus artemether/ lumefantrine EVIDENCE: PK: In 30 Ugandan HIV positive patients without malaria, artemether, DHA, lumefantrine concentrations were reduced by 77%, 75% and 55%, respectively. Byakika-Kibwika P IAC 2012 TUPE-054 PK: Similar reductions seen with rifampicin Lamorde et al 51st ICAAC 2011 So the issues now are: the patient has already self-medicated with ART/LUM; the magnitude of the interaction To Panel – would you proceed?

Outcome Symptoms resolved with artemether/lumefantrine treatment and patient continues ongoing HIV care at IDI

Issues for discussion Self-medication with antimalarials and limited capacity for pharmacovigilance in resource-limited settings Efavirenz and nevirapine lower exposure of critical malaria drugs Clinical outcomes data needed ? Potential for resistance

How about malaria treatment for patients receiving protease inhibitors? Any chance that this could be made into a second case, even if it is brief. I think you could develop the cardiotoxicity issue a bit – this will certainly be of interest.

Case June 2012 Low grade fever (on and off) Blood film: malaria AK, M, 52 yrs, city businessman HIV diagnosis (2004) Management CTX 960 mg OD (since 2004) d4T/3TC/NVP (since 2004) baseline CD4 77 cells/µL VL 17,000 copies (2008) TDF/3TC/LPV/r (since 2008) Last CD4 (2011) 350 cells/µL Referred to heart institute 2011 ECG normal Blood pressure normal Cholesterol Total: 230 mg/dL HDL: 50 mg/dL June 2012 Low grade fever (on and off) Blood film: malaria

Options: Lopinavir/ritonavir plus quinine ?

Options: Lopinavir/ritonavir plus quinine EVIDENCE: PK: In healthy volunteers, ritonavir increased the AUC and Cmax of quinine four-fold. Soyinka et al. Br J Clin Pharmacol (2010) Safety: ? Potential for increased toxicity at standard doses

Options: Lopinavir/ritonavir plus artemether/ lumefantrine ?

Options: Lopinavir/ritonavir plus artemether/ lumefantrine EVIDENCE: PK: Ugandan HIV+ patients without malaria (n = 32), lumefantrine concentrations increased by 386% while artemether decreased by 43% Byakika-Kibwika P, J Antimicrob Chemother (2012) PK: Lumefantrine markedly higher in SA patients on LPV/r T Kredo,CROI 2012 (Paper # 613) Efficacy: Randomized trial in Ugandan HIV+ children (n=176): 43% lower risk of malaria recurrence in lopinavir/ritonavir arm versus NNRTI arm. Achan J, CROI 2012 (Paper #26)

Safety?

Options: Lopinavir/ritonavir plus artemether/ lumefantrine EVIDENCE: Safety: Structurally similar to halofantrine which causes QT prolongation Single dose studies: No QTc prolongation in healthy volunteers or Ugandan patients German P, JAIDS 2009; Byakika-Kibwika P, Chem Res and Pract, 2011 However, lumefantrine accumulates with repeated dosing and no safety data with six-dose regimen

Acknowledgements www.hiv-druginteractionslite.org Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala Ivan Mambule Jane Achan Pauline Byakika-Kibwika Acknowledgements